Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1207 results
August 2016
-
Media ReleaseAirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatmentNew study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving…
-
Media ReleaseFDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseasesErelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is approved for all indications included in the reference product's…
-
Media ReleaseNovartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp13th International Biotechnology Leadership Camp focuses on potential of new technologies to fundamentally transform biomedical research and the pharmaceutical business Interactive program…
-
Media ReleaseExperten diskutieren am Novartis International BioCamp neue Technologien im GesundheitsbereichIm Zentrum des 13. International Biotechnology Leadership Camp steht das Potenzial neuer Technologien, die biomedizinische Forschung und die Pharmabranche grundlegend zu verändern Das interaktive…
-
Media ReleaseNovartis convie plusieurs experts au Novartis International BioCamp afin de discuter des nouvelles technologies en matière de santéLa 13e édition de l'International Biotechnology Leadership Camp explore les nouvelles technologies susceptibles de révolutionner la recherche biomédicale et l'industrie pharmaceutique. Un programme…
-
Media ReleaseNovartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MSThe Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression…
-
Media ReleaseSix leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of ImmunologyThe Basic Immunology Prize is awarded to John Kappler, Philippa Marrack and Harald von Boehmer for demonstrating that the ability of the immune system to discriminate "self" from "non-self" is…
-
Media ReleaseNovartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancerDesignation underscores the continuing unmet need of the HR+/HER2- advanced breast cancer population and the potential of LEE011 (ribociclib) as an effective new treatment option Results…
-
Media ReleaseAlcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucomaUS Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma The CyPass Micro-Stent is designed to…
July 2016
-
Media ReleaseNovartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospectsQ2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (…
-
Media ReleaseNovartis réalise un 2ème trimestre solide, malgré l'impact sur le trimestre du générique de Gleevec aux US; nouvelles positives importantes de l'innovation renforcent les perspectives de croissanceChiffre d'affaires net du T2 stable (0% tcc[1]), les produits de croissance[2] ayant compensé l'impact du générique de Gleevec Gilenya (USD 811 millions, +17% tcc) a continué de croître à un taux…
Pagination
- ‹ Previous page
- 1
- …
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- …
- 101
- › Next page